ALHC Stock Cash Flow Statements

Alignment Healthcare Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Alignment Healthcare Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

operating activities:
net income	15,653,000	-9,354,000	-31,064,000	-26,429,000	-24,003,000	-46,575,000	-47,231,000	-35,077,000	-28,494,000	-37,371,000	-56,995,000	-40,247,000	-11,580,000	-40,817,000	-47,834,000	-45,816,000	-44,762,000	-56,874,000
adjustments to reconcile net income to net cash from operating activities:
benefit from credit loss			0	28,000			0	40,000	50,000	1,000	0	39,000	58,000	53,000	37,000	28,000
loss on right of use assets						143,000
gain on sale of property and equipment			-1,000
depreciation and amortization	7,036,000	7,627,000	6,808,000	7,686,000	6,539,000	6,029,000	5,861,000	5,561,000	5,264,000	4,982,000	4,751,000	4,513,000	4,229,000	3,993,000	4,149,000	4,133,000	3,962,000	3,789,000
amortization-investment discount	-361,000	-370,000	-495,000	-322,000	-609,000	-1,153,000		-1,633,000	-1,365,000	-351,000
amortization-debt issuance costs	441,000	440,000	315,000	366,000	92,000	520,000		303,000	429,000	305,000
equity-based compensation	15,553,000	17,187,000	16,236,000	17,258,000	16,784,000	20,854,000		13,569,000	15,636,000	21,978,000
non-cash lease expense	-149,000	395,000	404,000	430,000	458,000	472,000	665,000	305,000	631,000	717,000	660,000	736,000	700,000	715,000	730,000	687,000	666,000	648,000
changes in operating assets and liabilities:
accounts receivable	-69,104,000	-60,155,000	-15,052,000	44,334,000	-18,238,000	-45,322,000	-14,226,000	-16,638,000	36,301,000	-32,387,000	-4,537,000	9,769,000	-13,559,000	-26,050,000	-10,877,000	18,772,000	-16,177,000	-9,326,000
prepaid expenses and other current assets	-12,533,000	-43,800,000	16,696,000	-1,588,000	1,665,000	-8,886,000	908,000	31,306,000	-19,291,000	-15,786,000	-5,614,000	-2,156,000	-1,507,000	-5,079,000	1,489,000	2,564,000	-4,846,000	-9,547,000
other assets	-29,000	-23,000	-17,000	-15,000	206,000	-114,000	-23,000	-7,000	-116,000	4,000	51,000	13,000	17,000	-167,000	636,000	2,000	12,000	-6,000
medical expenses payable	58,420,000	106,946,000	-7,337,000	-18,244,000	38,905,000	71,065,000	1,965,000	-3,764,000	21,528,000	15,535,000	-1,259,000	-2,476,000	18,908,000	29,077,000	-2,890,000	-7,703,000	7,036,000	16,069,000
accounts payable and accrued expenses	3,346,000	5,208,000	-4,295,000	1,462,000	1,325,000	48,000	-1,734,000	4,383,000	215,000	-9,211,000	11,713,000	5,182,000	-1,496,000	-1,656,000	880,000	1,925,000	-2,070,000	-298,000
deferred premium revenue	-80,000	157,000		194,000	-251,000	-59,000		-1,135,000	6,396,000	140,773,000
accrued compensation	10,662,000	-7,577,000	5,980,000	1,117,000	1,227,000	-2,505,000	-1,030,000	9,236,000	1,334,000	-2,966,000	-3,875,000	6,544,000	1,304,000	-364,000	-5,882,000	7,167,000	1,162,000	-3,691,000
lease liabilities	85,000	-65,000	-33,000	-71,000	-666,000	-755,000	-888,000	-457,000	-1,052,000	-1,113,000	-1,088,000	-1,098,000	-1,002,000	-1,026,000	-1,038,000	-991,000	-956,000	-832,000
net cash from operating activities	29,130,000	16,616,000	-8,711,000	26,190,000	23,529,000	-6,238,000	-187,466,000	5,992,000	37,177,000	85,110,000	-149,263,000	105,120,000	10,354,000	-11,638,000	-30,134,000	12,914,000	-23,449,000	-38,107,000
capex	-8,003,000	-8,252,000	-9,284,000	-9,280,000	-11,733,000	-11,121,000	-10,597,000	-9,553,000	-8,560,000	-7,285,000	-6,457,000	-6,548,000	-5,855,000	-4,914,000	-2,951,000	-5,947,000	-5,016,000	-4,446,000
free cash flows	21,127,000	8,364,000	-17,995,000	16,910,000	11,796,000	-17,359,000	-198,063,000	-3,561,000	28,617,000	77,825,000	-155,720,000	98,572,000	4,499,000	-16,552,000	-33,085,000	6,967,000	-28,465,000	-42,553,000
investing activities:
purchase of investments	-17,096,000	-17,905,000	-6,676,000	-35,524,000	-18,436,000	-21,564,000	-97,476,000	-124,639,000	-52,700,000	-104,243,000	0	-1,725,000	-250,000	-850,000	0	-1,675,000	-50,000	-750,000
sale of property and equipment			0
maturities of investments	17,295,000	22,695,000	10,040,000	20,230,000	57,135,000	75,390,000
sale of business
acquisition of property and equipment	-8,003,000	-8,252,000	-9,284,000	-9,280,000	-11,733,000	-11,121,000	-10,597,000	-9,553,000	-8,560,000	-7,285,000	-6,457,000	-6,548,000	-5,855,000	-4,914,000	-2,951,000	-5,947,000	-5,016,000	-4,446,000
net cash from investing activities	-6,664,000	-3,462,000	-5,920,000	-24,560,000	26,966,000	42,705,000	-1,018,000	-9,607,000	-26,210,000	-110,428,000	-8,107,000	-8,128,000	-5,855,000	-6,127,000	-2,951,000	-6,997,000	-6,421,000	-4,446,000
financing activities:
proceeds from long-term debt			330,000,000	0
payment of employment taxes related to release of restricted stock			0	0	0	-350,000
debt issuance costs	0	-26,000	-8,280,000	0							-595,000
proceeds from stock option exercises	1,616,000	207,000
contributions from noncontrolling interest holders			0	0	0	15,000	45,000	0	30,000	30,000
net cash from financing activities	1,616,000	181,000	106,875,000	0	49,488,000	-335,000	45,000	0	30,000	30,000	-527,000	17,220,000			0	0	-3,529,000	363,659,000
net increase in cash	24,082,000	13,335,000	92,244,000	1,630,000	99,983,000	36,132,000					-157,897,000	114,212,000	4,399,000	-17,765,000	-33,085,000	5,917,000	-33,399,000	321,106,000
cash, cash equivalents and restricted cash at beginning of period	0	434,942,000	0	0	0	204,954,000	0	0	0	411,299,000
cash, cash equivalents and restricted cash at end of period	24,082,000	448,277,000	92,244,000	1,630,000	99,983,000	241,086,000	-188,439,000	-3,615,000	10,997,000	386,011,000
supplemental disclosure of cash flow information:
cash paid for interest			6,555,000	5,355,000	5,072,000	5,175,000	5,222,000	4,957,000	4,709,000	4,277,000	0	16,882,000	2,807,000	2,758,000	2,799,000	2,780,000	2,731,000	2,682,000
supplemental non-cash investing and financing activities:
acquisition of property in accounts payable	32,000	85,000	-42,000	-10,000	-34,000	156,000	-58,000	75,000	32,000	10,000	-243,000	58,000	-99,000	331,000	-91,000	20,000	-56,000	474,000
cash and cash equivalents	24,082,000	446,184,000	92,559,000	1,293,000	100,104,000	238,903,000	-188,739,000	-3,615,000	10,997,000	384,261,000
restricted cash in other assets	0	2,093,000	-315,000	337,000	-121,000	2,183,000	300,000	0	0	1,750,000	0	0	0	1,750,000	800,000	50,000
total	24,082,000	448,277,000	92,244,000	1,630,000	99,983,000	241,086,000	-188,439,000	-3,615,000	10,997,000	386,011,000	-157,897,000	114,212,000	4,399,000	450,585,000	-33,085,000	5,917,000	-33,399,000	528,917,000
(gain) loss on right of use assets
amortization of payment-in-kind interest											0
loss on disposal of property and equipment
loss on extinguishment of debt											0
payment-in-kind interest											0	-16,292,000	1,100,000	1,070,000	1,079,000	1,064,000	1,039,000	1,015,000
purchase of business, net of cash received											-1,650,000	-1,280,000	0	-1,113,000
repurchase of noncontrolling interest											0	0
repayment of long-term debt											0
proceeds from exercise of stock options
purchase of business in accounts payable											130,000	135,000	0	240,000
debt issuance costs in accounts payable
gain on right of use assets				-8,000
amortization-debt issuance costs and investment discount											242,000	468,000	574,000	566,000	573,000	571,000	560,000	550,000
equity-based compensation and common stock payments											22,885,000	18,687,000	12,099,000	28,047,000	28,814,000	30,511,000	30,887,000	20,388,000
asset acquisition, net of cash received															0	0
sale of investments									35,050,000	1,100,000	0	1,425,000	250,000	750,000	0	625,000	50,000	750,000
equity repurchase															0	0	0	-1,474,000
issuance of long-term debt											0
issuance of common stock															0	0	0	390,600,000
common stock issuance costs															0	0	-3,544,000	-25,467,000
(gain) loss on sublease								0
net decrease in cash								-3,615,000	10,997,000	-25,288,000
loss on sublease											0	1,000
noncurrent liabilities
proceeds from the sale of property and equipment
cash and restricted cash at beginning of period											0	0	0	468,350,000	0	0	0	207,811,000
cash and restricted cash at end of period											-157,897,000	114,212,000	4,399,000	450,585,000	-33,085,000	5,917,000	-33,399,000	528,917,000
cash											-157,897,000	114,212,000	4,399,000	448,835,000	-33,885,000	5,867,000	-33,799,000	528,417,000
common stock issuance costs included in accounts payable and accrued expenses																		3,532,000
purchase of noncontrolling interest															0	0
benefit from doubtful accounts																		8,000
restricted cash in restricted and other assets																		500,000

We provide you with 20 years of cash flow statements for Alignment Healthcare stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Alignment Healthcare stock. Explore the full financial landscape of Alignment Healthcare stock with our expertly curated income statements.

The information provided in this report about Alignment Healthcare stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.